File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical outcome of micrometastasis in the lung in stage IA persistent gestational trophoblastic disease

TitleClinical outcome of micrometastasis in the lung in stage IA persistent gestational trophoblastic disease
Authors
KeywordsCT thorax
Drug response
Micrometastasis
Recurrence
Stage IA PGTD
Issue Date1998
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 1998, v. 70 n. 2, p. 192-194 How to Cite?
AbstractBackground. Computed tomography (CT) of the thorax can be used in the staging of persistent gestational trophoblastic disease (PGTD). However, the prognostic significance of micrometastasis in the lung detected by CT of the thorax has not been well documented. The aim of the study is to define the effect of micrometastasis on the clinical course of the disease. Methods. Thirty-five patients who had nonmetastatic GTD underwent CT thorax examination before treatment in the Department of Obstetrics and Gynaecology, University of Hong Kong. All patients had workups which showed no evidence of metastasis and were diagnosed as FIGO stage IA. They all received methotrexate (MTX) infusion therapy. Results. Three groups of patients were identified based on the thorax CT findings. Sixteen patients (45.7%) showed no evidence of micrometastasis on CT thorax. Two of them (12.5%) had poor response to MTX with unsatisfactory fall in serum hCG levels requiring change of chemotherapy to actinomycin D. Nine patients had suspicious micrometastasis and one (11.1%) of them needed change of MTX. Ten patients had micrometastasis and one (10%) of them needed change of MTX. There was only one recurrence and it was in the suspicious micrometastasis group (11.1%). There was no statistically significant difference in the rate of poor drug response or recurrence among the three groups of patients. Conclusions. Micrometastases in the lung do not affect the clinical outcome of patients with FIGO stage IA disease. CT thorax is not essential in the staging of GTD.
Persistent Identifierhttp://hdl.handle.net/10722/87071
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorChan, FLen_HK
dc.contributor.authorAu, VWKen_HK
dc.contributor.authorCheng, DKLen_HK
dc.contributor.authorNg, TYen_HK
dc.contributor.authorWong, LCen_HK
dc.date.accessioned2010-09-06T09:24:57Z-
dc.date.available2010-09-06T09:24:57Z-
dc.date.issued1998en_HK
dc.identifier.citationGynecologic Oncology, 1998, v. 70 n. 2, p. 192-194en_HK
dc.identifier.issn0090-8258en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87071-
dc.description.abstractBackground. Computed tomography (CT) of the thorax can be used in the staging of persistent gestational trophoblastic disease (PGTD). However, the prognostic significance of micrometastasis in the lung detected by CT of the thorax has not been well documented. The aim of the study is to define the effect of micrometastasis on the clinical course of the disease. Methods. Thirty-five patients who had nonmetastatic GTD underwent CT thorax examination before treatment in the Department of Obstetrics and Gynaecology, University of Hong Kong. All patients had workups which showed no evidence of metastasis and were diagnosed as FIGO stage IA. They all received methotrexate (MTX) infusion therapy. Results. Three groups of patients were identified based on the thorax CT findings. Sixteen patients (45.7%) showed no evidence of micrometastasis on CT thorax. Two of them (12.5%) had poor response to MTX with unsatisfactory fall in serum hCG levels requiring change of chemotherapy to actinomycin D. Nine patients had suspicious micrometastasis and one (11.1%) of them needed change of MTX. Ten patients had micrometastasis and one (10%) of them needed change of MTX. There was only one recurrence and it was in the suspicious micrometastasis group (11.1%). There was no statistically significant difference in the rate of poor drug response or recurrence among the three groups of patients. Conclusions. Micrometastases in the lung do not affect the clinical outcome of patients with FIGO stage IA disease. CT thorax is not essential in the staging of GTD.en_HK
dc.languageengen_HK
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_HK
dc.relation.ispartofGynecologic Oncologyen_HK
dc.subjectCT thoraxen_HK
dc.subjectDrug responseen_HK
dc.subjectMicrometastasisen_HK
dc.subjectRecurrenceen_HK
dc.subjectStage IA PGTDen_HK
dc.titleClinical outcome of micrometastasis in the lung in stage IA persistent gestational trophoblastic diseaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0090-8258&volume=70&spage=192&epage=194&date=1998&atitle=Clinical+outcome+of+micrometastasis+in+the+lung+in+stage+IA+persistent+gestational+trophoblastic+diseaseen_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1006/gyno.1998.5088en_HK
dc.identifier.pmid9740689-
dc.identifier.scopuseid_2-s2.0-0032143302en_HK
dc.identifier.hkuros39921en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032143302&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume70en_HK
dc.identifier.issue2en_HK
dc.identifier.spage192en_HK
dc.identifier.epage194en_HK
dc.identifier.isiWOS:000076260500007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridChan, FL=55160087200en_HK
dc.identifier.scopusauthoridAu, VWK=6701783057en_HK
dc.identifier.scopusauthoridCheng, DKL=7402806161en_HK
dc.identifier.scopusauthoridNg, TY=7402229853en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats